Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Tenax Therapeutics (TENX) Non Operating Investment Income (2016 - 2017)

Tenax Therapeutics' Non Operating Investment Income history spans 4 years, with the latest figure at $10444.0 for Q4 2017.

  • For Q4 2017, Non Operating Investment Income fell 84.7% year-over-year to $10444.0; the TTM value through Dec 2017 reached -$2526.0, up 97.72%, while the annual FY2021 figure was -$70.0, 113.26% down from the prior year.
  • Non Operating Investment Income for Q4 2017 was $10444.0 at Tenax Therapeutics, up from -$3767.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $68261.0 in Q4 2016 and bottomed at -$140237.0 in Q1 2016.
  • The 4-year median for Non Operating Investment Income is -$3213.5 (2017), against an average of -$6812.7.
  • The largest YoY upside for Non Operating Investment Income was 96.59% in 2017 against a maximum downside of 109.58% in 2017.
  • A 4-year view of Non Operating Investment Income shows it stood at -$23254.0 in 2014, then rose by 8.48% to -$21283.0 in 2015, then soared by 420.73% to $68261.0 in 2016, then tumbled by 84.7% to $10444.0 in 2017.
  • Per Business Quant, the three most recent readings for TENX's Non Operating Investment Income are $10444.0 (Q4 2017), -$3767.0 (Q3 2017), and -$2660.0 (Q2 2017).